Table 1.

List of cell therapy products used in cartilage repair area available on the world market

Product name	Company	Country	Approval	Indication	Remarks
Carticel®	Vericel	US	1997 FDA	Cartilage defects of the femoral condyle (medial, lateral, or trochlea)	First ACI/2017 phased out
MACI®	Vericel	US	2016 FDA	Full-thickness cartilage defects of the knee	Second ACI
ChondroCelect®	TiGenix	EU	2009 EMA	Cartilage defects of the femoral condyle of the knee	First ACI/2016 withdrawn
MACI®	Vericel	EU	2013 EMA	Full-thickness cartilage defects of the knee	Second ACI/2014 suspended
Spherox (chondrosphere®)	co.don	EU	Jul 2017 EMA	Articular cartilage defects of the femoral condyle and knee patella	Third ACI
Chondron™	Sewon Cellontech	Korea	2001/2008 MFDS	Articular cartilage defect (knee/ankle)	Second ACI
CARTISTEM®	Medipost	Korea	2012 MFDS	Osteoarthritis due to degeneration or repetitive trauma	Allogeneic umbilical cord blood-derived MSC drug
Invossa™ (TissueGene-C)	Kolon Life Sciences	Korea	Jul 2017 MFDS	Moderate knee osteoarthritis with persistent symptoms despite ≥3 months of conservative treatment	TGF-β-expressing allogeneic chondrocytes
JACC	Japan Tissue Engineering	Japan	2012 MHLW	Traumatic arthritis, osteochondritis dissecans of the knee	Second ACI

The list includes marketed products announced by each national regulatory authority as of 1 August 2017. For the United States, the FDA-approved products are listed, but not 361 HCT/P products. For the European Medicines Agency (EMA), the EMA-approved products are listed, but not the hospital exemption products. For Korea, MFDS-approved products are listed. In Japan, the MHLW-approved products are listed